Abstract 17430: Targeting DNA Hypermethylation With Hypomethylating Drugs: Implications for Pulmonary Arterial Hypertension
EL-Kabbout Reem, François Potus(Queen's University), Steeve Provencher(Institut universitaire de cardiologie et de pneumologie de Québec), Sébastien Bonnet(Institut universitaire de cardiologie et de pneumologie de Québec), Sarah‐Eve Lemay(SNC-Lavalin (Canada)), Charlotte Romanet(Canadian Heart Research Centre), Olivier Boucherat, Charlie Théberge(Canadian Heart Research Centre), ANTONELLA ABI SLEIMAN(Institut universitaire de cardiologie et de pneumologie de Québec), Sandra Breuils Bonnet(Université Laval), Mabrouka Salem(King Khalid University), Alice Bourgeois, Sandra Martineau(Canadian Heart Research Centre)
Cited by 0
Related Papers
A Mitochondria-K+ Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer Growth
|Cancer Cell|2007|1.5k
Novel Mutations and Decreased Expression of the Epigenetic Regulator <i>TET2</i> in Pulmonary Arterial Hypertension
|Circulation|2020|120
Defining the clinical validity of genes reported to cause pulmonary arterial hypertension
|Genetics in Medicine|2023|73
Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension
|American Journal of Respiratory and Critical Care Medicine|2020|34
ATP citrate lyase drives vascular remodeling in systemic and pulmonary vascular diseases through metabolic and epigenetic changes
|Science Translational Medicine|2024|33